Skip to content

Discovery could change the landscape of autoimmune therapy, according to study

Myasthenia gravis (MG) is a chronic autoimmune disease in which antibodies block communication between nerves and muscles, leading to skeletal muscle weakness. It can cause double vision, difficulty swallowing, and occasional severe breathing problems, among other symptoms. Many autoimmune diseases like MG, as well as a number of other human diseases, result from the inability to regulate the activity of IgG antibodies – these diseases are collectively referred to as IgG-mediated pathologies. In a paper published this month in Cell, researchers at Emory University have discovered a family of enzymes that reduce IgG-mediated pathologies in diseases like MG. The findings, conducted in mouse models, show that a particular enzyme (an endoglycosidase called CU43) was particularly effective in treating diseases caused by overactive antibodies. The newly discovered enzyme was used to treat a range of different IgG-mediated pathologies in mice and proved… 

more »Entdeckung könnte laut Studie die Landschaft der Autoimmuntherapie verändern

Aujeszkysche Krankheit: Kein Impfstoff für Hunde und Katzen

Die Aujeszkysche Krankheit (AK) stellt eine ernsthafte Bedrohung für Hunde und Katzen dar und kommt in Wildschweinpopulationen vor. Diese Viruserkrankung, die primär Schweine befällt, verläuft bei Hunden und Katzen immer tödlich[1][2]. Der Erreger, das Suide Herpesvirus 1, auch als Pseudorabiesvirus bekannt, ist in Deutschland vor allem in Wildschweinpopulationen verbreitet[7]. Die Übertragung auf Hunde und Katzen […] Aujeszkysche Krankheit: Kein Impfstoff für Hunde und Katzen

Mpox Klade I erstmals in Deutschland nachgewiesen

Die neue und mutmaßlich gefährlichere Affenpocken-Variante „Klade I“, wegen der die Weltgesundheitsorganisation eine Notlage ausgerufen hat, ist erstmals in Deutschland nachgewiesen worden. Die Infektion durch die neue Klade Ib sei am Freitag gemeldet worden, teilte das Robert-Koch-Institut am Dienstag mit. Die betroffene Person soll sich demnach im Ausland infiziert haben. Das RKI geht aktuell weiterhin […] Neue Affenpocken-Variante erstmals in Deutschland nachgewiesen

First Targeted Treatment for Grade 2 IDH-Mutant Glioma

Servier Canada announced the approval and commercial availability of VORANIGO™ (vorasidenib tablets), the first targeted therapy for the treatment of Grade 2 isocitrate dehydrogenase (IDH)-mutant glioma in adults and pediatric patients aged 12 years and older, following surgery. VORANIGO™ offers glioma patients the convenience of a once-daily oral treatment, providing them with an opportunity to actively manage their disease. Canada is the second country after the United States to receive regulatory authorization for VORANIGO™. Gliomas are the second-most common type of cancer in Canadians under 40 years old and the second-most common cause of cancer-related deaths in this group.1 These slow-growing brain tumours spread within the brain leading to disruptions in neurological function, seizures, and cognitive impairment. Diffuse gliomas with IDH mutations represent the most common malignant primary brain tumours diagnosed in adults younger than 50 years of age. They… 

more »First Targeted Treatment for Grade 2 IDH-Mutant Glioma

Künstliche „Nase“ erschnüffelt verdorbenes Obst und Fleisch

Although the sense of smell has always played an important role in fighting diseases like plague and tuberculosis, the human nose is generally not sensitive enough to be used as a reliable diagnostic tool. A new artificial "nose" that mimics our sense of smell, however, could now make it possible to detect undiagnosed diseases, dangerous gases, and food beginning to spoil. Researchers say their sensor distinguishes the various gases it was tested on with 96.7 percent accuracy. This result is not only on par with the performance of the best electronic noses currently available, but in some areas even surpasses them. To understand this, here's how the antenna nose works: The antenna sends radio signals of various frequencies into the environment. It then analyzes how they are reflected back. The behavior of the signals changes depending on...

more »Artificial "nose" sniffs out spoiled fruit and meat

Dotmatics Introduces Luma Antibody & Protein Engineering Solution for End-to-End Antibody Discovery

Dotmatics®, a leader in R&D scientific software connecting science, data, and decision-making, today announced the launch of Dotmatics Luma™ Multimodal R&D Solutions in support of the discovery and development of therapeutics across multiple modalities of biopharmaceutical science. The first solution is the Luma Antibody & Protein Engineering solution, a comprehensive end-to-end solution for streamlining the antibody discovery and development process, with an emphasis on monoclonal and multispecific antibodies. The Luma Antibody & Protein Engineering Solution and other future multimodal solutions combine the Dotmatics Luma Scientific Intelligence Platform and key Dotmatics scientific tools, thoughtfully composed within Luma. Together, these solutions will offer researchers a multimodal approach to therapeutic discovery supporting CAR-T cell discovery, siRNA, antibody-drug conjugates (ADCs), CRISPR therapeutics, and vaccine discovery.

Wood chip bioreactors rid wastewater of drugs and nitrates

In a new University of Illinois Urbana-Champaign study, researchers show how a simple system using wood chips and a bit of clarified sawdust can drastically reduce nitrogen, phosphorus, and several common drugs in wastewater. "Even at low concentrations, drugs and personal care products (PPCPs) can degrade water quality, disrupt ecosystems, promote antibiotic resistance, and lead to bioaccumulation in wildlife. While nutrients like [...] Wood chip bioreactors rid wastewater of drugs and nitrates

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center

The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene inhalation injury. The collaboration aims to determine whether opaganib can advance into further definitive U.S. government-sponsored development under the FDA’s Animal Rule pathway to approval Used as a chemical weapon during World War I, phosgene, a toxic, colorless chemical, is today widely used in industrial processes for the manufacture of plastics and pesticides. The U.S. Environmental Protection Agency (EPA) identified 123 sites in the United States that could potentially expose millions of people to phosgene due to plant malfunction or bioterrorism[1] Phosgene inhalation can be extremely dangerous, causing significant, even fatal, respiratory injury. No known approved antidote or reversal agent currently exists, and, if approved, opaganib may provide potential for stockpiling for emergency use in the event of a… 

more »RedHill Announces Collaboration with a Leading U.S. Academic Medical Center

New Study: CaRi-Heart® Technology Highly Cost-Effective in the NHS

Caristo Diagnostics, a global leader in cardiovascular disease diagnostics and risk prediction, today announced the findings of a new peer-reviewed research study demonstrating that its novel CaRi-Heart® technology could be implemented across the UK’s National health Service (NHS) in a highly cost-effective way to transform cardiac care and reduce overall cardiac deaths by 12%. The study, entitled „Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine Coronary Computed Tomography Angiography,“ was published this month in the European Heart Journal: Quality of Care and Clinical Outcomes. The study was conducted by clinical investigators from the UK, USA and Australia, and shows that the CaRi-Heart care pathway is a highly cost-effective approach to prevent adverse outcomes from coronary artery disease (CAD), aligning with the UK Government’s vision for the future of the NHS. Coronary… 

more »New Study: CaRi-Heart® Technology Highly Cost-Effective in the NHS

Elevidys erreicht primären Endpunkt in Phase-3-Studie nicht

  • News

Eine klinische Studie der Phase 3 zu Elevidys (Delandistrogen Moxeparvovec), einer Gentherapie für die Muskeldystrophie Duchenne, hat ihren primären Endpunkt nicht erreicht, wie aus in Nature Medicine veröffentlichten Ergebnissen hervorgeht . In derselben Ausgabe des Journals erschien ein News and Views- Artikel über die Studie. In der Studie konnte Elevidys nach 52 Wochen keine statistisch… Elevidys erreicht primären Endpunkt in Phase-3-Studie nicht